Age-related macular degeneration (AMD), diabetic macular edema (DME), glaucoma, and uveitis are among the leading causes of ... visual loss worldwide. The societal impact of the loss of vision from these diseases is tremendous. The development and eventual availability of pharmacotherapeutic agents for these diseases have helped to preserve vision and reduce blindness for millions of patients around the globe. However, there are still many unmet needs: the high cost of drugs (often resulted from the financi
Developments of ophthalmic pharmacotherapeutic agents and devices consist of different stages before a drug or device is approved by the Food and Drug Agency (FDA). Proceeding to the next stage often requires the success and lack of significant safety concerns from the previous stages. Only a very small number of compounds investigated in phase 1 will eventually make it to phase 2 and 3 for further testing. As such, pharmaceutical and device sponsors are very careful and often reluctant to study pharmacothe
GORC is established to fulfill the unmet needs to provide coordinating support for single centered and ... multi-centered first-in-human, first-to-assess, novel and original clinical trials to evaluate a pharmacotherapeutic agent or an imaging device for ocular diseases. As a not-for-profit organization, GORC aims to work with Clinician-scientists, clinical research teams, other profit and non-profit organizations in the US and throughout the world facilitate the conduct of trials and studies at the lowest